Close Menu

NEW YORK – The US Food and Drug Administration has granted AstraZeneca and Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki (Enhertu) breakthrough therapy designation as a treatment for HER2-mutated, metastatic non-small cell lung cancer that has progressed after platinum-based therapy. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.